Doheny Asset Management CA Grows Holdings in Uniqure NV (NASDAQ:QURE)

Doheny Asset Management CA raised its position in Uniqure NV (NASDAQ:QURE) by 52.2% during the second quarter, Holdings Channel.com reports. The firm owned 23,055 shares of the biotechnology company’s stock after buying an additional 7,910 shares during the period. Uniqure accounts for about 1.5% of Doheny Asset Management CA’s holdings, making the stock its 26th largest holding. Doheny Asset Management CA’s holdings in Uniqure were worth $1,802,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in QURE. US Bancorp DE lifted its holdings in Uniqure by 275.5% in the 2nd quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 427 shares in the last quarter. Botty Investors LLC purchased a new position in Uniqure in the 2nd quarter valued at about $78,000. Rockefeller Capital Management L.P. purchased a new position in Uniqure in the 2nd quarter valued at about $78,000. Aperio Group LLC purchased a new position in Uniqure in the 2nd quarter valued at about $83,000. Finally, NumerixS Investment Technologies Inc purchased a new position in Uniqure in the 2nd quarter valued at about $125,000. Institutional investors own 74.70% of the company’s stock.

A number of research analysts have issued reports on the stock. Chardan Capital restated a “buy” rating on shares of Uniqure in a report on Tuesday, September 3rd. Guggenheim downgraded shares of Uniqure from a “buy” rating to a “neutral” rating in a research note on Monday, July 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $94.00 price objective (up previously from $81.00) on shares of Uniqure in a research note on Monday, July 8th. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Finally, Mizuho began coverage on shares of Uniqure in a research note on Thursday. They set a “buy” rating and a $67.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $77.25.

In related news, Director Philip Astley-Sparke sold 6,460 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $60.12, for a total transaction of $388,375.20. Following the completion of the sale, the director now owns 12,406 shares of the company’s stock, valued at approximately $745,848.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $56.48, for a total transaction of $451,840.00. Following the sale, the chief executive officer now directly owns 391,230 shares of the company’s stock, valued at approximately $22,096,670.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,460 shares of company stock valued at $2,031,415. Corporate insiders own 2.91% of the company’s stock.

NASDAQ QURE opened at $47.48 on Friday. Uniqure NV has a 12 month low of $21.98 and a 12 month high of $82.49. The company has a 50-day moving average of $55.22 and a 200-day moving average of $62.12. The company has a debt-to-equity ratio of 0.51, a current ratio of 8.07 and a quick ratio of 8.07. The company has a market cap of $1.84 billion, a P/E ratio of -20.29 and a beta of 0.96.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, July 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The company had revenue of $2.47 million for the quarter, compared to analyst estimates of $1.53 million. As a group, equities research analysts anticipate that Uniqure NV will post -3.22 EPS for the current year.

Uniqure Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: Quantitative Easing

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).

Institutional Ownership by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.